Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity an Italian experience

Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity : an Italian experience

Copyright © 2022 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 242(2022) vom: 01. Sept., Seite 109091
1. Verfasser: Infantino, Maria (VerfasserIn)
Weitere Verfasser: Morena, Lorenza, Di Pietro, Massimo Antonio, Romanin, Benedetta, Cimolato, Barbara, Rocca, Beatrice Anna Luisa, Tunnera, Silvia, Modi, Giulia, Tilli, Marta, Grossi, Valentina, Lari, Barbara, Cerutti, Helena, Tesi, Giulia, Anrò, Valentina, Cartocci, Alessandra, Benucci, Maurizio, Veneziani, Francesca, Casprini, Patrizia, Manfredi, Mariangela
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article COVID-19 Inflammatory markers Respiratory support Risk assessment suPAR Biomarkers Interleukin-6 Leukocyte L1 Antigen Complex Receptors, Urokinase Plasminogen Activator Tumor Necrosis Factor-alpha
Beschreibung
Zusammenfassung:Copyright © 2022 Elsevier Inc. All rights reserved.
BACKGROUND: The soluble urokinase Plasminogen Activator Receptor (suPAR) has been identified as a reliable marker of COVID-19 severity, helping in personalizing COVID-19 therapy. This study aims to evaluate the correlation between suPAR levels and COVID-19 severity, in relation to the traditional inflammatory markers
METHODS: Sera from 71 COVID-19 patients were tested for suPAR levels using Chorus suPAR assay (Diesse Diagnostica Senese SpA, Italy). suPAR levels were compared with other inflammatory markers: IL-1β, IL-6, TNF-α, circulating calprotectin, neutrophil and lymphocyte counts, and Neutrophil/Lymphocytes Ratio (NLR). Respiratory failure, expressed as P/F ratio, and mortality rate were used as indicators of disease severity
RESULTS: A positive correlation of suPAR levels with IL-6 (r = 0.479, p = 0.000), TNF-α (r = 0.348, p = 0.003), circulating calprotectin (r = 0.369, p = 0.002), neutrophil counts (r = 0.447, p = 0.001), NLR (r = 0.492, p = 0.001) has been shown. Stratifying COVID-19 population by suPAR concentration above and below 6 ng/mL, we observed higher levels of circulating calprotectin (10.1 μg/mL, SD 7.9 versus 6.4 μg/mL, SD 7.5, p < 0.001), higher levels of P/F ratio (207.5 IQR 188.3 vs 312.0 IQR 127.8, p = 0.013) and higher mortality rate. Median levels of suPAR were increased in all COVID-19 patients requiring additional respiratory support (Nasal Cannula, Venturi Mask, BPAP and CPAP) (6.5 IQR = 4.9) compared to the group at room air (4.6 IQR = 4.2)
CONCLUSION: suPAR levels correlate with disease severity and survival rate of COVID-19 patients, representing a promising prognostic biomarker for the risk assessment of the disease
Beschreibung:Date Completed 13.09.2022
Date Revised 21.12.2022
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2022.109091